Drug Sample Reporting Must Be Streamlined, PhRMA Tells FDA
Executive Summary
FDA could be flooded with “millions of duplicative signatures” every time a health care practitioner requests a drug sample, the trade group warns.
You may also be interested in...
Drug Sample Reporting: FDA Doesn’t Want Signatures, But Firms Need Them On File
Revisions to draft guidance implementing Affordable Care Act streamline some requirements – allowing sponsors, authorized distributors, or even third parties to submit reports to FDA.
FDA’s TV Ad Review Is Unconstitutional, PhRMA Says, Or Maybe Should Be A Reg
A draft guidance that outlines six categories of drug ads FDA wants submitted for prior review is a violation of advertisers’ free speech rights, the industry group argues. Other comments float a storyboard compromise.
Drug Sample Distribution Reporting Deadline Extended By FDA
FDA is giving manufacturers six more months to provide HHS with information on the distribution of drug samples as it plans further guidance; the Affordable Care Act mandated that the data be submitted by April 1.